Premium
Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma
Author(s) -
Markman Maurie,
Cleary Stephen,
Pfeifle Craig,
Howell Stephen B.
Publication year - 1986
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19860701)58:1<18::aid-cncr2820580105>3.0.co;2-c
Subject(s) - medicine , cisplatin , mesothelioma , debulking , nephrotoxicity , sodium thiosulfate , surgery , chemotherapy , regimen , population , toxicity , ovarian cancer , cancer , pathology , inorganic chemistry , chemistry , environmental health
Twenty‐one patients with malignant mesothelioma were treated with an experimental Intracavitary chemotherapy regimen of weekly intraperitoneal or intrapleural cisplatin (90–100 mg/m 2 ) with simultaneous intravenous sodium thiosulfate delivered to protect against cisplatin‐induced nephrotoxicity. One of eight patients (12.5%) receiving intrapleural therapy and nine of 13 patients receiving intraperitoneal therapy demonstrated objective evidence of a clinical response, including three surgically defined major tumor regressions (23%). Patients receiving intrapleural treatment had more advanced disease prior to therapy than those receiving intraperitoneal therapy. It was concluded that intraperitoneal cisplatin is an active treatment program for intra‐abdominally localized mesothelioma. Additional investigation of intrapleural cisplatin should be undertaken in a patient population with less advanced disease or following surgical debulking. Cancer 58:18–21, 1986.